Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X about a paper he co-authored with colleagues published in Taylor and Francis Online:
“Clinical outcomes of allogeneic cell transplantation for patients with chronic myeloid leukemia
Allogeneic transplant in CML AP/BP and TKI-resistant CML-CP (TKI era): 5-year OS is approximately 56%, relapse-free survival is approximately 40%.
Lymphoid blast phase do better than myeloid blast phase.
Collaboration between Mayo Clinic and UAB.”
Title: Clinical outcomes of allogeneic cell transplantation for patients with chronic myeloid leukemia
Authors: Benjamin McCormick, Anthony Findley, Kendall Diebold, Garrett Bourne, Maris Hardee, James Foran, Mohamed Kharfan-Dabaja, Hemant Murthy, Madiha Iqbal, Naseema Gangat, Lisa Sproat, Jeanne Palmer, William Hogan, Kebede Begna, Mark Litzow, Ayalew Tefferi, Mrinal Patnaik, Ravi Bhatia, Omer Jamy, Talha Badar
You can read the Full Article in Taylor and Francis Online.
More posts featuring Talha Badar.